Loading patent…
AssigneeRenovo Limited
InventorsMark Ferguson, Sharon O'Kane, Hugh Laverty, Nick Occleston, Jane Kelly, Wayne Burrill
Estimating the term…
The invention provides pharmaceutical compositions comprising TGF-β superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF-β superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-β superfamily members in a pharmaceutical composition. Uses of the pharmaceutical compositions are also described, particularly with reference to wound healing and fibrosis. Furthermore, the invention discloses medicaments for the prevention or reduction of injection pain.
A pharmaceutical composition comprising a TGF-β2 and a sugar provided at sufficient concentration to allow improved recovery and/or increased biological activity of the TGF-β2.
A soluble pharmaceutical composition comprising a TGF-β2 and a sugar, wherein the sugar is provided in such a proportion that, on dissolution of the composition to achieve a physiological solution, the sugar is provided at sufficient concentration to allow improved recovery and/or increased biological activity of the TGF-β2.
A soluble pharmaceutical composition comprising a TGF-β2, a source of sodium ions, and a sugar, the quantities of the source of sodium ions and of the sugar being such that on dissolution of the composition to produce a sodium concentration of between 130 and 160 mEq/L, the concentration of the sugar is sufficient to allow improved recovery and/or increased biological activity of the TGF-β2.
15-16. (canceled)
(canceled)
A method for improving the recovery and/or increasing the biological activity of TGF-β3 incorporated in a pharmaceutical composition comprising adding a sugar to the composition.
39-40. (canceled)
A method for preventing or reducing injection pain of a soluble pharmaceutical composition comprising adding a sugar to the pharmaceutical composition, wherein the pharmaceutical composition further comprises a therapeutic active agent able to promote wound healing.
46-47. (canceled)
Dependencies are inferred from the claim text.